Trial Profile
A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2022
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Antineoplastics
- Indications Astrocytoma; Glioma
- Focus Therapeutic Use
- 23 May 2022 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 30 May 2013 Planned end date changed from 1 Oct 2012 to 1 Sep 2016 as reported by ClinicalTrials.gov.